

**REMARKS**

Upon entry of the present amendment, claims 1-10, 12 and 14-33 are pending in the above-referenced patent application and are currently under examination. Claims 1 and 24 have been amended. Claims 11 and 13 have been canceled. Claim 12 has been withdrawn. Reconsideration of the application is respectfully requested.

Claim 1 has been amended to the scope of claim 13, imidazopyridazines. Support for the amendment can be found in the claims as filed and throughout the specification.

Claim 24 has been amended to remove non-elected subject matter.

Applicants believe the claim amendments add no new matter to the claims.


In response to the Restriction Requirement, Applicants elect, the invention of Group II, claims 1-11 (part), 13 and 14-33 (part) drawn to imidazopyridazines, classified in class 544, subclass 262. Accordingly, Applicants submit that the requirement under 35 U.S.C. § 121 has been met.

**CONCLUSION**

In view of the foregoing, Applicants believe the pending claims in this Application are in condition for substantive review on the merits. Favorable consideration is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Alexander R. Trimble  
Reg. No. 52,301

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
ART:art  
61331310 v1